Dutch Biologic Monitor: Fatigue Among Biologic Recipients Across a Range of Immune-Mediated Inflammatory Diseases

Clinical Care Options (CCO) expert commentary on new data on IBD pathogenesis and management from the 2021 virtual Crohn’s & Colitis Congress

Anita Afzali, MD, MPH, FACG Released: March 5, 2021

Commentary by Dr. Vinod Chandran on using interleukin inhibitors secukinumab and guselkumab for axial manifestations of psoriatic arthritis, from CCO

Vinod Chandran, MBBS, MD, DM, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: January 11, 2021 Expired: January 10, 2022

Commentary from Dr Jim Treat on counseling parents and children about pros and cons of systemic therapy for pediatric plaque psoriasis, from CCO

Jim Treat, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: January 8, 2021 Expired: January 7, 2022

CME for CCO on when to use interleukin inhibitors in psoriatis arthritis: biologic DMARD or MTX naive? IL-17A secukinumab, ixekizumab; IL-12/23 ustekinumab

Vinod Chandran, MBBS, MD, DM, PhD Alexis Ogdie, MD, MSCE Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Released: December 29, 2020 Expired: December 28, 2021

Guidelines and Therapies

Head-to-Head Studies